Professor Ingo Hilgendorf
University of Freiburg, Freiburg (Germany)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
The physician`s perspective: what prevents us from keeping LDL-C lower for longer? Who are the patients that need more help?
Event: ESC Congress 2022
Topic: Lipid-Lowering Agents
Session: Lower for longer: reframing the clinical goal for LDL-C. The lower the better is no longer enough
NLRP3 mediates atheromatous plaque macrophage proliferation
Event: ESC Congress 2022
Topic: Leukocytes, Inflammation, Immunity
Session: Atherosclerosis and inflammation
Incorporating Lp(a) into risk classification for patients with ASCVD.
Event: ESC Congress 2022
Topic: Cardiovascular Risk Assessment
Session: Uncovering the hidden risk: why lipoprotein(a) testing is crucial
Lipid im- and exporters differentially determine macrophage turnover in the plaque
Event: ESC Congress 2017
Topic: Lipids
Session: Lipids, cardiac pathology
SYK inhibitor fostamtinib protects from early but not established atherosclerosis when local macrophage proliferation dominates lesion turnover
Event: ESC Congress 2016
Topic: Atherosclerosis
Session: Best Posters in atherosclerosis
ESC 365 is supported by
